UKI-1

UKI-1 (WX-UK1) is a potent urokinase-type plasminogen activator (uPA) inhibitor with a Ki of 0.41 μM. UKI-1 is also a low molecular weight serine protease inhibitor. UKI-1 is a potent antimetastatic agent and inhibits the invasive capacity of carcinoma cells[1][2].

Product Specifications

CAS Number

[220355-63-5]

Product Name Alternative

WX-UK1; UKI-1C

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

PAI-1; Ser/Thr Protease

Type

Reference compound

Related Pathways

Metabolic Enzyme/Protease

Applications

COVID-19-immunoregulation

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/UKI-1.html

Purity

96.13

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

O=C(N1CCN(C([C@@H](NS(=O)(C2=C(C(C)C)C=C(C(C)C)C=C2C(C)C)=O)CC3=CC=CC(C(N)=N)=C3)=O)CC1)OCC

Molecular Formula

C32H47N5O5S

Molecular Weight

613.81

Precautions

H302, H315, H319, H335

References & Citations

[1]Ertongur S et al. Inhibition of the invasion capacity of carcinoma cells by WX-UK1, a novel synthetic inhibitor of the urokinase-type plasminogen activator system. Int J Cancer. 2004 Jul 20;110 (6) :815-24.|[2]Ewa Zeslawska et al. Crystals of the urokinase type plasminogen activator variant βc-uPA in complex with small molecule inhibitors open the way towards structure-based drug design. J Mol Biol. 2000 Aug 11;301 (2) :465-75.